{"prompt": "['2017N331008_00', 'CONFIDENTIAL', '208090', 'baseline is not considered an AE.', 'd.', 'Results in persistent disability/incapacity', \"The term disability means a substantial disruption of a person's ability to conduct\", 'normal life functions.', 'This definition is not intended to include experiences of relatively minor medical', 'significance such as uncomplicated headache, nausea, vomiting, diarrhea,', 'influenza, and accidental trauma (e.g., sprained ankle) which may interfere with', 'or prevent everyday life functions but do not constitute a substantial disruption.', 'e.', 'Is a congenital anomaly/birth defect', 'f.', 'Other situations:', 'Medical or scientific judgment should be exercised in deciding whether SAE', 'reporting is appropriate in other situations such as important medical events that', 'may not be immediately life-threatening or result in death or hospitalization but', 'may jeopardize the participant or may require medical or surgical intervention to', 'prevent one of the other outcomes listed in the above definition. These events', 'should usually be considered serious.', 'Examples of such events include invasive or malignant cancers, intensive treatment', 'in an emergency room or at home for allergic bronchospasm, blood dyscrasias or', 'convulsions that do not result in hospitalization, or development of drug dependency', 'or drug abuse.', '11.8.3.', 'Definition of Cardiovascular Events', 'Cardiovascular Events (CV) Definition:', 'Investigators will be required to fill out the specific CV event page of the eCRF for the', 'following AEs and SAEs:', 'Myocardial infarction/unstable angina', 'Congestive heart failure', 'Arrhythmias', 'Valvulopathy', 'Pulmonary hypertension', 'Cerebrovascular events/stroke and transient ischemic attack', 'Peripheral arterial thromboembolism', 'Deep venous thrombosis/pulmonary embolism', 'Revascularization', '108']['2017N331008_06', 'CONFIDENTIAL', '208090', '11.8.4.', 'Recording AE and SAE', 'AE and SAE Recording', 'When an AE/SAE occurs, it is the responsibility of the investigator to review all', 'documentation (e.g., hospital progress notes, laboratory, and diagnostics reports)', 'related to the event.', 'The investigator will then record all relevant AE/SAE information in the eCRF.', \"It is not acceptable for the investigator to send photocopies of the participant's\", 'medical records to ViiV/GSK/PPD in lieu of completion of the AE/SAE eCRF', 'page.', 'There may be instances when copies of medical records for certain cases are', 'requested by ViiV/GSK/PPD. In this case, all participant identifiers, with the', 'exception of the subject number, will be redacted on the copies of the medical', 'records before submission to ViiV/GSK/PPD.', 'The investigator will attempt to establish a diagnosis of the event based on signs,', 'symptoms, and/or other clinical information. Whenever possible, the diagnosis', '(not the individual signs/symptoms) will be documented as the AE/SAE.', 'Assessment of Intensity', 'The investigator will make an assessment of intensity for each AE and SAE reported', 'during the study and assign it to 1 of the categories in the Division of AIDS Table for', 'Grading the Severity of Adult and Pediatric Adverse Events (\"DAIDS AE Grading', 'Table\") in Section 11.10:', 'Grade 1/ Mild', 'Grade 2/ Moderate', 'Grade 3/ Severe', 'Grade 4/ Potentially life threatening', 'Grade 5/ Death', \"An event is defined as 'serious' when it meets at least 1 of the predefined outcomes as\", 'described in the definition of an SAE, NOT when it is rated as severe.', '109']['2017N331008_06', 'CONFIDENTIAL', '208090', 'Assessment of Causality', 'The investigator is obligated to assess the relationship between study intervention', 'and each occurrence of each AE/SAE.', 'A \"reasonable possibility\" of a relationship conveys that there are facts, evidence,', 'and/or arguments to suggest a causal relationship, rather than a relationship', 'cannot be ruled out.', 'The investigator will use clinical judgment to determine the relationship.', 'Alternative causes, such as underlying disease(s), concomitant therapy, and other', 'risk factors, as well as the temporal relationship of the event to study intervention', 'administration will be considered and investigated.', \"The investigator will also consult the Investigator's Brochure (IB) and/or Product\", 'Information, for marketed products, in his/her assessment.', 'For each AE/SAE, the investigator must document in the medical notes that', 'he/she has reviewed the AE/SAE and has provided an assessment of causality.', 'There may be situations in which an SAE has occurred and the investigator has', 'minimal information to include in the initial report to ViiV/GSK. However, it is', 'very important that the investigator always make an assessment of causality', 'for every event before the initial transmission of the SAE data to', 'ViiV/GSK/PPD.', 'The investigator may change his/her opinion of causality in light of follow-up', 'information and send an SAE follow-up report with the updated causality', 'assessment.', 'The causality assessment is one of the criteria used when determining regulatory', 'reporting requirements.', 'Follow-up of AE and SAE', 'The investigator is obligated to perform or arrange for the conduct of', 'supplemental measurements and/or evaluations as medically indicated or as', 'requested by ViiV/GSK/PPD to elucidate the nature and/or causality of the AE or', 'SAE as fully as possible. This may include additional laboratory tests or', 'investigations, histopathological examinations, or consultation with other health', 'care professionals.', 'If a participant dies during participation in the study or during a recognized', 'follow-up period, the investigator will provide ViiV/GSK with a copy of any', 'post-mortem findings including histopathology.', '110']\n\n###\n\n", "completion": "END"}